Vericel Corp. (VCEL)

[lasers]

$VCEL Ixmyelocel-T results have been fantastic as a result of their culturing of the bone marrow in their bioreactors.



Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy

http://investors.vcel.com/releasedetail.cfm?ReleaseID=1012614


$VCEL pivotal Phase2B

https://www.clinicaltrials.gov/ct2/show/NCT01670981?term=Ixmyelocel-T&rank=1




IMO CardiAMP is at least 3 years away from a FDA decision



https://www.clinicaltrials.gov/ct2/show/NCT02438306?term=CardiAMP&rank=1


Estimated Enrollment: 250
Study Start Date: December 2016
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)